UK-headquartered global biopharma company GSK has agreed to acquire 100% of the outstanding equity interests (including all options and other incentive equity) in IDRx, a US-based, clinical-stage biopharmaceutical company dedicated…
UK: GSK to acquire IDRx for up to US$1.15bn
…
…






